OSUR

Business Context and Reporting Period

Company: OraSure Technologies, Inc. (OTI)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: OTI develops, manufactures, and markets diagnostic products (HIV, HCV, Syphilis, Sickle Cell, COVID-19) and sample management solutions (genomics, microbiome). The company operates as a single reporting segment. In November 2025, OTI acquired BioMedomics, Inc., adding the SickleSCAN rapid test for sickle cell disease. In December 2024, the company acquired Sherlock Biosciences, Inc., expanding its molecular diagnostics pipeline.

Key Financial Metrics

Note: The filing text does not provide a specific total debt figure; liabilities are primarily composed of operating lease liabilities ($13.0 million) and acquisition-related contingent consideration ($27.7 million).

Material Changes vs. Prior Period

• Revenue Decline: Total net revenues dropped 38% to $115.0 million. This was driven by a 99% collapse in COVID-19 diagnostics revenue (from $45.1M to $0.6M) due to contract fulfillment and lower demand, a 25% decline in Sample Management Solutions due to a major customer bankruptcy, and a 12% drop in Diagnostics revenue (HIV/HCV) due to reduced international funding and domestic program cuts.
• Operating Expenses: Research and Development (R&D) expenses surged 63% to $42.5 million, primarily due to clinical trials for the CT/NG device and integration of Sherlock Biosciences. General and Administrative (G&A) expenses rose 3% to $47.7 million due to legal fees (NowDx litigation) and acquisition costs.
• Acquisitions: The company acquired BioMedomics (Nov 2025) for approximately $4.0 million (including contingent consideration) and Sherlock Biosciences (Dec 2024) for approximately $28.3 million (including contingent consideration).
• Business Exits: The company fully exited the Risk Assessment Testing business (revenue down 78%) and the Molecular Services business (revenue down 100%) during the period.
• Stock Repurchases: The company repurchased $15.0 million of its common stock under a $40.0 million program authorized in March 2025.

Guidance, Outlook, and Risks

• Outlook: Management expects COVID-19 revenues to continue declining. The company is focused on commercializing new products, including the SickleSCAN test and the CT/NG molecular self-test (510(k) submitted Dec 2025). The company expects existing cash reserves to fund operations for the next 12 months.
• Management Commentary: The decline in gross margin was attributed to negative product mix (lower sales of high-margin InteliSwab and Genomics products) and lower absorption of fixed overhead costs. The company is consolidating manufacturing in Pennsylvania to improve efficiency.
• Key Risks:
  • Government Funding: Significant revenue reliance on U.S. and international government funding (CDC, BARDA, Global Fund) which is subject to political uncertainty and budget freezes.
  • Regulatory: Delays in FDA approvals for new products (CT/NG, Colli-Pee) could impact future growth. The company faces risks related to the regulation of Laboratory-Developed Tests (LDTs).
  • Customer Concentration: One non-commercial customer accounted for 24% of revenue in 2024, dropping to 3% in 2025. A commercial customer accounted for 15% of accounts receivable in 2025.
  • Supply Chain: Reliance on sole-source suppliers for critical components (antigens, nitrocellulose) creates vulnerability to disruptions.
  • Legal: Ongoing litigation against NowDiagnostics, Inc. regarding trade secrets and misappropriation.

Investor Verification Checklist

• Cash Burn Rate: Verify the sustainability of the $199.3 million cash balance given the $68.7 million net loss and $49.0 million cash used in operating activities.
• Post-Pandemic Revenue Mix: Assess the ability of HIV, HCV, and Genomics products to replace the $45 million in lost COVID-19 revenue.
• Acquisition Integration: Monitor the performance and regulatory progress of Sherlock Biosciences (CT/NG test) and BioMedomics (SickleSCAN) to ensure they generate expected returns.
• Government Contract Exposure: Evaluate the impact of potential U.S. government funding freezes or policy changes on the public health market segment.
• Contingent Consideration: Review the fair value adjustments of the $27.7 million contingent consideration liability, which impacted the 2025 operating loss by $4.6 million.